SCHEMBL1877409

SCHEMBL1877409

CC(C)Oc1cc(CN2CCC(Nc3ccnc4ccccc34)CC2)cc(OC(C)C)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SSTR5 P35346 5/20 0.62
MCHR1 Q99705 1/20 0.51
KMT2A Q03164 3/20 0.48
KDM4E B2RXH2 3/20 0.48
MEN1 O00255 2/20 0.48
ALDH1A1 P00352 1/20 0.48
HRH1 P35367 1/20 0.44
HTR2B P41595 1/20 0.44
ROCK2 O75116 2/20 0.42
ROCK1 Q13464 1/20 0.42
EZH2 Q15910 1/20 0.42
NSD2 O96028 1/20 0.41
LMNA P02545 2/20 0.41
MAPT P10636 2/20 0.41
HTT P42858 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
NTSR1 P30989 1/20 0.41
FAAH O00519 1/20 0.40
HRH3 Q9Y5N1 1/20 0.40
DYRK1A Q13627 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1876665 0.88 SSTR5 (0.56) SSTR5MCHR1KMT2AKDM4EMEN1
SCHEMBL1880219 0.88 MEN1 (0.66) SSTR5MCHR1KMT2AKDM4EMEN1
SCHEMBL1880245 0.84 SSTR5 (0.54) SSTR5MCHR1HRH1HTR2BEZH2
SCHEMBL1878181 0.83 SSTR5 (0.55) SSTR5MCHR1KMT2AKDM4EMEN1
SCHEMBL2420486 0.82 SSTR5 (0.59) SSTR5MCHR1KMT2AKDM4EMEN1
SCHEMBL3782674 0.80 SSTR5 (0.60) SSTR5ALDH1A1HRH1HTR2BLMNA
SCHEMBL1881042 0.80 SSTR5 (0.52) SSTR5MCHR1KMT2AKDM4EMEN1
SCHEMBL1880914 0.80 SSTR5 (0.64) SSTR5MCHR1KMT2AKDM4EMEN1
SCHEMBL1876062 0.80 SSTR5 (0.64) SSTR5MCHR1KMT2AKDM4EMEN1
SCHEMBL1880457 0.80 KDM4E (0.54) SSTR5MCHR1KMT2AKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7939661-B2 Antidiabetic agents; somatostatin receptor subtype 5 modulators; noninsulin dependent diabetes mellitus; side effect reduction; synthesis HOFFMAN-LA ROCHE INC. (US) 2011-05-10 US claimed
EP-2066658-A1 PYRIDINE- AND QUINOLINE-PYRIMIDINE-DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2009-06-10 EP claimed
WO-2008031735-A1 PYRIDINE- AND QUINOLINE-PYRIMIDINE-DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2008-03-20 WO claimed
US-20080064697-A1 PYRIDINE, QUINOLINE AND PYRIMIDINE DERIVATIVES HOFFMAN-LA ROCHE INC. 2008-03-13 US claimed
US-7939661-B2 Antidiabetic agents; somatostatin receptor subtype 5 modulators; noninsulin dependent diabetes mellitus; side effect reduction; synthesis HOFFMAN-LA ROCHE INC. (US) 2011-05-10 US disclosed
EP-2066658-A1 PYRIDINE- AND QUINOLINE-PYRIMIDINE-DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2009-06-10 EP disclosed
WO-2008031735-A1 PYRIDINE- AND QUINOLINE-PYRIMIDINE-DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2008-03-20 WO disclosed
US-20080064697-A1 PYRIDINE, QUINOLINE AND PYRIMIDINE DERIVATIVES HOFFMAN-LA ROCHE INC. 2008-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064697-A1 PYRIDINE, QUINOLINE AND PYRIMIDINE DERIVATIVES SSTR5, SSTR3, NPY5R SSTR5 1/4885MCHR1 207/4885KMT2A 4252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.